Overview: Insulin Antibodies High Sensitivity TestIntroduction: The Insulin Antibodies High Sensitivity Test detects insulin antibodies with high sensitivity to diagnose autoimmune diabetes, causing high blood sugar. Aligned with 2023 ADA guidelines, it uses advanced immunoassay for high specificity, supporting diabetes screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected early or atypical autoimmune diabetes.
Other Names: Insulin Ab HS Assay, High Sensitivity Autoimmune Diabetes Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: High-sensitivity insulin antibody testing emerged in the 2000s with advanced diabetes research. Immunoassay-based methods improved diagnostic precision for early autoimmune diabetes.
Purpose: Detects insulin antibodies with high sensitivity to diagnose autoimmune diabetes, guides treatment, and evaluates patients with high blood sugar.
Test Parameters: 1. Insulin Antibodies (High Sensitivity)
Pretest Condition: No fasting required. Collect serum or saliva. Report history of high blood sugar, fatigue, or diabetes symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document high blood sugar, fatigue, weight loss, or family history of diabetes. Include current medications, especially insulin.
Consent: Written consent required, detailing the tests purpose, diabetes implications, and risks of blood or saliva collection.
Procedural Considerations: Uses high-sensitivity immunoassay to detect insulin antibodies in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for early autoimmune diabetes diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive insulin antibodies suggest early type 1 diabetes or insulin autoimmune syndrome, guiding insulin therapy. Negative results may require further autoimmune testing.
Specialist Consultation: Consult an endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: GAD65 antibodies, IA-2 antibodies, or C-peptide to confirm autoimmune diabetes diagnosis.
Test Limitations: High sensitivity increases false positives; clinical correlation is needed. Other autoimmune conditions may produce antibodies.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Atkinson MA, 2022.
